Cor Therapeutics Inc. (CORR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (413)	4/26/1999 11:32:00 AM
From: Edscharp	Read Replies (1) of 712

From Medical Technology Stock Letter - April 22, 1999 "COR Therapeutics reported earnings for the first quarter on April 20th. The company reported a net loss of $11.8 million, or $0.48 per share, on revenues of $7.5million, for the quarter ended March 31st, versus a net loss of $5.3 million, $0.22 per share, on revenues of $8.4 million, for the same quarter in 1998. Integrilin sales totaled $11.3 million for the quarter, exceeding consensus estimates of $9.0 million. Current sales are running at a $1.0 million per week rate. The company has increased estimates for Integrilin sales to $65 - $70 million this year, $175 - $200 million for 2000, and $300 - $350 million for 2001. The company expects to begin turning a profit around mid-2000. CORR is a buy under $18."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next